E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10068341 |
E.1.2 | Term | HIV-1 infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate antiviral efficacy of 3 doses (60, 120 and 180 mg) of BMS-955176, and EFV, each when given in combination with TDF/FTC in treatment-naïve subjects by determining the proportion of treatment-naïve subjects with plasma HIV-1 RNA < 40 c/mL at Week 24 |
|
E.2.2 | Secondary objectives of the trial |
- To assess the antiviral efficacy of BMS-955176 and EFV by determining the proportion of subjects with plasma
HIV-1 RNA < 40 c/mL at Weeks 48, and 96
- To assess the antiviral efficacy of BMS-955176 and EFV by determining the proportion of subjects with plasma
HIV-1 RNA < 200 c/mL at Weeks 24, 48, and 96
- To assess the emergence of HIV drug resistance among samples selected for drug resistance testing
- To assess efficacy of BMS-955176 and EFV, by using mean changes from baseline in log10 HIV-1 RNA, CD4+ T-cell counts, and percentage of CD4+ T-cells
- To assess the safety and tolerability of BMS-955176 in treatment-naïve subjects by measuring frequency of SAEs and AEs leading to discontinuation
- To assess disease progression as measured by the occurrence of new AIDS defining events (CDC Class C events)
- To characterize the pharmacokinetics of BMS-955176 when co-administered with TDF and FTC in treatment-naïve HIV-1 infected subjects. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1- Pharmacogenetics Blood Sample Amendment 01 dated 28-January-2015, version 1.0:
The objective of this Amendment is to permit the collection and storage of blood samples for use in future exploratory pharmacogenetic research. Bristol-Myers Squibb will use DNA obtained from the blood sample and health information collected from the main clinical trial, AI468038 to study the association between genetic variation and drug response. Bristol-Myers Squibb may also use the DNA to study the causes and further progression of HIV. Samples from this study may also be used in conjunction with pharmacogenetic research results from other clinical studies to accomplish this objective.
2- Optional Week 2 Intensive PK Substudy:
Subjects with anemia, defined as Hemoglobin < 11.0 g/dL, should be excluded from participation in the Week 2 Intensive PK Substudy.
Subjects in all arms will have the opportunity to participate in an elective Intensive PK Substudy visit at Week 2 (window for visit: Day 12-16). Approximately 48 subjects, 12 subjects from each arm, are expected to participate in the substudy; BMS may allow the substudy to over-enroll in an effort to have a sufficient number of complete datasets. |
|
E.3 | Principal inclusion criteria |
- Men and non-pregnant women, at least 18 years of age
- Antiretroviral treatment-naïve; defined as no current or previous exposure to > 1 week of an antiretroviral drug
Plasma HIV-1 RNA > or = to 1000 copies/mL
- CD4 T-cell count > 200 cells/mm3
|
|
E.4 | Principal exclusion criteria |
- Resistance or partial resistance to any study drug determined by tests at Screening
- Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors, (Please see protocol for further information on these exclusionary mutations)
- Chronic HBV/HCV
- Blood tests that inidcate normal liver function (see protocol)
- Hemoglobin < 8.0 g/dL and Platelets < 50,000 cells/mm3
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the proportion of subjects with plasma HIV-1 RNA < 40 c/mL at Week 24. This will be conducted as a sensitivity
analysis that compliments the snapshot analysis. This uses the last on treatment plasma HIV-1 RNA measurement within an FDA-specified visit window to determine response. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1- The antiviral efficacy will be determined by the proportion of subjects with plasma HIV-1 RNA < 40 c/mL at Weeks 48 and 96 using a
sensitivity analysis that compliments the snapshot analysis.
2- The antiviral efficacy will also be assessed by the proportion of subjects with plasma HIV-1 RNA < 200 c/mL at Weeks 24, 48, and 96
using the FDA snapshot algorithm approach with positive response
defined as HIV-1 RNA < 200 c/mL
3- The emergence of HIV drug resistance among samples selected for drug resistance testing will be assessed using the most recent version of the IAS-USA list of HIV-1 drug resistance mutations
4- Changes from baseline in log10 HIV-1 RNA and in CD4+ T-cell counts, and changes in the percentage of CD4+ T-cells over time will be
assessed using on-treatment laboratory results and pre-specified visit windows
5- The frequency of SAEs and AEs leading to discontinuation (DC) will be tabulated directly from the case report forms (CRFs). The summary will count the number of subjects that have at least one event
6- The occurrence of new AIDS defining events (CDC Class C events) will be tabulated from the CRFs. The summary will count the number of subjects that have at least one event
7- The steady-state plasma PK of BMS-955176 will be assessed using the intensive PK data, collected at Week 2 from a subset of subjects |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. at Weeks 48 and 96
2. at Weeks 24, 48 and 96
3. at Weeks 24, 48 and 96
4. at Weeks 24, 48 and 96
5. at Weeks 24, 48 and 96
6. at Weeks 24, 48 and 96
7. at Week 2
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 43 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Canada |
Chile |
Mexico |
South Africa |
Thailand |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 11 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |